摘要
背景与目的:新辅助化疗是目前乳腺癌研究领域的热点之一,该研究探讨多西他赛加吡柔比星行乳腺癌新辅助化疗的疗效及影响因素。方法:47例乳腺癌新辅助化疗患者术前穿刺取病理学标本,采用免疫组化法检测ER、PR、CerbB-2。分析获得病理学完全缓解(pCR)与患者年龄、组织学分级、化疗前淋巴结状态及ER、PR、CerbB-2表达的相关性。结果:ER阳性的患者获得pCR(0%)的比率低于ER阴性者(27.27%)。差异有显著性(P=0.0012)。PR阳性患者的pCR率(9.38%)低于PR阴性者(90.63%),差异有显著性(P<0.01)。CerbB-2过表达者pCR率(33.33%)高于非CerbB-2过表达者(9.74%)(P<0.01),组织学分级(SBR)高者的pCR率高于分级低者(Ⅲ级比Ⅱ级:25%比10.34%)(P=0.0000),年龄、化疗前淋巴结状态与pCR率无明显相关性。结论:ER、PR、CerbB-2、组织学分级可能成为多西他赛加吡柔比星新辅助化疗乳腺癌患者指导治疗和预测预后的重要指标。
Background and purpose： Neoadjuvant chemotherapy is one of the hot studied area in breast cancer research. Our aim was to explore the relationship between the clinical effect, pathological changes and the neoadjuvant chemotherapy containing THP and docetaxel on breast cancer. Methods： The expression of ER, PR and CerbB-2 in breast cancer tissue of patients who had received neoadjuvant chemotherapy were detected by immunohistochemistry method. The relationship of age, ER, PR, CerbB-2, pathological stage and axillary lymph node metastasis with pathological complete response（pCR） was analysed. Results： For the patients after neoadjuvant chemotherapy, the pCR of the positive ER（0%）, PR（9.38%） was lower than that of negative ER（20.27）, PR（90.63%） respectively. The pCR of the positive CerbB-2（33.33%） was higher than that of negative CerbB-2（9.74%, P〈0.01）. The poor differentiation tumor（Grade III, 25%） had more pCR rate than intermediate（Grade II, 25%）. There was no relationship between age, axillary lymph node metastasis and pCR. Conclusion： The ER, PR, CerbB-2 and pathological grade may be the important index for treatment and prognosis of patients with breast cancer who received neoadjuvant chemotherapy with docetaxel ＋ THP.
出处
《中国癌症杂志》
CAS
CSCD
2008年第11期828-831,共4页
China Oncology
